Why Johnson & Johnson Will Move the Dow Tomorrow

On Monday, the Dow Jones Industrials (DJINDICES: ^DJI  ) managed to climb back above the 17,000 level, rising by triple digits right out of the gate and holding on to gains of 130 points as of 11:45 a.m. EDT. Earnings season kicks into high gear this week, and much of today's rise came in the wake of better-than-expected performance from a former Dow component bank. Yet even though financial companies will play a big role in the Dow's earnings this week, Johnson & Johnson (NYSE: JNJ  ) is also set to play a pivotal role in setting the tone of the new earnings season.

Source: Johnson & Johnson.

Johnson & Johnson will issue its earnings release tomorrow morning, with its most recent quarterly report coming out at around 7:45 a.m. EDT. After that, the Dow component company will have its earnings meeting and conference call at 8:30 a.m. EDT to discuss the results, with a live webcast available at Johnson & Johnson's investor-relations website.

Investors are enthusiastic about Johnson & Johnson's earnings prospects, as the stock has risen to all-time highs. Expected growth of around 5.5% in revenue and 4% in earnings per share might seem somewhat modest for a stock hitting new record levels, but unlike many of its peers among the Dow Jones Industrials, Johnson & Johnson has convinced investors that it has some strong growth prospects that could accelerate in the future.

Specifically, Johnson & Johnson has banked on the continuing success of its pharmaceutical division in order to drive gains for the future. In recent quarters, most or all of Johnson & Johnson's overall growth has come from its pharma segment, with much more sluggish performance and even outright declines in some cases for its medical-device and consumer goods businesses. For its part, Johnson & Johnson still sees some opportunities for better results in those two lagging divisions, but the company has taken a more measured approach in focusing on efforts with the highest chance of reaching favorable outcomes, rather than simply aiming to grow those businesses more broadly. Steps like the completion of its $4 billion sale of its Ortho-Clinical Diagnostics business to Carlyle Group point to J&J's overall strategy of focusing on its best prospects.

Investors will want to see that pharma can sustain the pace of its growth. Last quarter, Johnson & Johnson saw impressive results up and down its sales lists, with treatments like psoriasis drug Stelara and prostate-cancer fighter Zytiga seeing revenue soar. More well-established products like its Remicade arthritis drug didn't see such huge percentage gains, but they nevertheless contributed to overall growth for the company. As Remicade approaches patent expiration beginning next year in Europe, Johnson & Johnson investors will increasingly look at the company's pipeline to make sure that it can replace revenue losses from patent-cliff issues.

Johnson & Johnson's results will move the Dow tomorrow, and the entire pharmaceutical sector will be watching to see if the company can sustain the pace of its recent growth. Good news from Johnson & Johnson could send its fellow drug stocks within the Dow Jones Industrials and beyond higher, and that in turn could spur on the Dow's bull run.

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 3027933, ~/Articles/ArticleHandler.aspx, 8/28/2015 3:48:47 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Dan Caplinger

Dan Caplinger has been a contract writer for the Motley Fool since 2006. As the Fool's Director of Investment Planning, Dan oversees much of the personal-finance and investment-planning content published daily on With a background as an estate-planning attorney and independent financial consultant, Dan's articles are based on more than 20 years of experience from all angles of the financial world.

Today's Market

updated 6 hours ago Sponsored by:
DOW 16,654.77 369.26 2.27%
S&P 500 1,987.66 47.15 2.43%
NASD 4,812.71 115.17 2.45%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

8/27/2015 4:35 PM
^DJI $16654.77 Up +369.26 +2.27%
JNJ $96.22 Up +1.11 +1.17%
Johnson & Johnson CAPS Rating: ****